VERACYTE, INC.

VCYT

VERACYTE, INC.

VCYT

Insider Sentiment (TTM):

Last Purchase:-Last Sale:2026-06-18Shares Purchased (TTM):0Shares Sold (TTM):480,111

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:85,270,513Shares Outstanding:79,536,601Institutional Ownership Pct.:107.21%

Earnings Market Reaction:

Filing Date:2026-07-31Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value	300	263	363	316	219	186	239	274	236	209	216	202
Debt Securities Held To Maturity Excluding Accrued…	186	176	50	51	101	101	50	-	-	-	0	0
Accounts Receivable Net Current	54	50	45	48	51	54	47	49	50	47	40	39
Inventory Raw Materials And Supplies	23	21	21	20	25	24	22	20	19	18	16	16
Prepaid Expense And Other Assets Current	13	12	10	15	18	18	15	14	16	16	13	14
Assets Current	575	522	488	449	415	383	372	357	321	290	286	271
Property Plant And Equipment And Finance Lease Rig…	22	23	22	19	19	23	23	21	22	22	21	19
Operating Lease Right Of Use Asset	35	36	37	37	39	48	48	17	18	11	10	11
Intangible Assets Net Excluding Goodwill	83	86	89	92	96	99	102	109	113	116	89	124
Goodwill	767	767	767	767	773	754	746	762	752	754	703	693
Restricted Cash And Cash Equivalents Noncurrent	-	-	-	2	2	2	2	1	1	1	1	1
Restricted Cash Noncurrent	2	2	2	-	-	-	2	-	-	-	-	-
Other Assets Noncurrent	3	1	1	1	1	7	7	8	7	6	6	6
Assets	1,486	1,436	1,406	1,368	1,344	1,315	1,300	1,275	1,234	1,200	1,115	1,125
Liabilities And Stockhold…
Liabilities Current
Accounts Payable Current	8	7	5	6	11	16	9	10	12	12	13	13
Accrued Liabilities Current	48	43	49	48	44	36	44	44	43	30	38	35
Contract With Customer Liability Current	1	1	1	0	1	2	2	2	2	3	2	2
Business Combination Contingent Consideration Liab…	1	1	1	14	13	14	17	7	7	7	3	3
Operating Lease Liability Current	6	4	4	4	6	7	8	7	7	6	5	5
Other Liabilities Current	-	-	0	0	0	0	0	0	0	0	0	0
Liabilities Current	63	56	60	72	76	75	79	70	72	58	61	57
Deferred Income Tax Liabilities Net	1	1	1	1	1	1	1	1	1	1	1	4
Business Combination Contingent Consideration Liab…	0	0	-	-	-	-	-	-	-	-	-	-
Operating Lease Liability Noncurrent	34	35	36	36	44	43	43	12	14	8	8	9
Other Liabilities Noncurrent	-	-	0	0	1	0	0	1	1	1	1	1
Business Combination Contingent Consideration Liab…	-	1	0	1	1	1	1	14	14	13	1	0
Liabilities	98	92	96	110	123	120	124	99	102	81	71	71
Stockholders Equity
Preferred Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Additional Paid In Capital Common Stock	1,720	1,701	1,695	1,685	1,671	1,660	1,656	1,646	1,627	1,617	1,536	1,528
Retained Earnings Accumulated Deficit	-323	-349	-378	-419	-438	-437	-444	-449	-464	-470	-468	-440
Accumulated Other Comprehensive Income Loss Net Of…	-8	-8	-8	-8	-12	-29	-36	-21	-31	-29	-24	-34
Stockholders Equity	1,388	1,344	1,310	1,258	1,221	1,195	1,176	1,176	1,133	1,119	1,044	1,054
Liabilities And Stockholders Equity	1,486	1,436	1,406	1,368	1,344	1,315	1,300	1,275	1,234	1,200	1,115	1,125
Preferred Stock Par Or Stated Value Per Share	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001
Preferred Stock Shares Authorized	5	5	5	5	5	5	5	5	5	5	5	5
Preferred Stock Shares Issued	0	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Shares Outstanding	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Par Or Stated Value Per Share	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001
Common Stock Shares Authorized	125	125	125	125	125	125	125	125	125	125	125	125
Common Stock Shares Issued	80	80	79	79	79	78	78	77	77	76	73	73
Shares Outstanding	80	80	79	79	79	78	78	77	77	76	73	73

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	12.50%	46.86%	37.44%	-	-	-	-	-	-	-	-	-
2025	-14.74%	-12.27%	-19.10%	9.61%	20.81%	32.70%	2.82%	-7.71%	-8.19%	-17.83%	-12.77%	-0.70%
2024	3.13%	7.70%	17.89%	16.64%	24.84%	22.11%	15.02%	7.45%	17.33%	-8.46%	-10.41%	-16.00%
2023	-	-	-	-0.22%	-16.55%	-26.31%	14.64%	18.83%	13.52%	-10.45%	-17.41%	-2.85%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Liquidity Ratios
Current Ratio	9.16	9.31	8.15	6.23	5.43	5.10	4.73	5.08	4.44	5.00	4.66	4.74
Quick Ratio	8.96	9.10	7.98	6.02	5.19	4.86	4.55	4.88	4.22	4.72	4.46	4.50
Working Capital	512.04M	466.06M	428.44M	377.07M	338.25M	308.03M	293.63M	286.54M	248.77M	232.37M	224.38M	213.90M
Leverage & Debt
Debt to Equity	0.07	0.07	0.07	0.09	0.10	0.10	0.11	0.08	0.09	0.07	0.07	0.07
Debt Ratio	0.07	0.06	0.07	0.08	0.09	0.09	0.10	0.08	0.08	0.07	0.06	0.06
Efficiency & Turnover
Asset Turnover TTM	0.40	0.39	0.38	0.37	0.37	0.37	0.37	0.35	0.33	0.32	0.32	0.30
Days Sales Outstanding TTM	34.10	35.00	32.18	35.62	38.52	39.56	35.58	37.80	42.32	44.79	42.66	42.21
Receivables Turnover TTM	10.70	10.43	11.34	10.25	9.48	9.23	10.26	9.66	8.62	8.15	8.56	8.65
Per Share Metrics
Diluted EPS TTM	1.40	1.08	0.82	0.38	0.34	0.41	0.31	-0.12	-0.70	-0.91	-1.02	-0.69
Free Cash Flow Per Share TTM	2.08	1.95	1.61	1.25	1.07	1.01	0.83	0.73	0.52	0.35	0.47	0.40
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Margin Metrics
Gross Profit Margin TTM	71.71%	70.92%	70.10%	68.53%	68.26%	68.02%	66.88%	78.90%	78.64%	77.81%	81.00%	69.12%
Operating Profit Margin TTM	18.82%	14.31%	11.17%	5.00%	2.89%	5.11%	3.62%	-5.53%	-16.84%	-21.29%	-23.76%	-16.23%
Net Profit Margin TTM	20.37%	16.25%	12.83%	6.12%	5.50%	7.13%	5.41%	-2.18%	-13.52%	-18.16%	-20.61%	-14.56%
Growth Metrics
Net Revenue Growth (1Y)	17.28%	16.91%	16.01%	16.41%	19.91%	23.42%	23.46%	23.95%	21.59%	20.66%	21.76%	21.01%
Net Income Growth (1Y)	334.72%	166.31%	174.89%	-427.11%	-148.73%	-148.48%	-132.44%	-81.45%	85.96%	125.83%	103.51%	15.52%
EPS Growth (1Y)	326.12%	161.26%	167.55%	-420.00%	-147.58%	-146.44%	-130.81%	-82.46%	76.10%	118.02%	100.44%	13.70%
Valuation Metrics
P/E TTM	41.03	29.11	49.86	89.15	80.46	70.00	125.48	-282.86	-30.69	-24.30	-26.86	-32.54
P/B TTM	3.38	1.91	2.53	2.15	1.74	1.94	2.58	2.23	1.46	1.48	1.91	1.54
P/S TTM	8.36	4.73	6.40	5.46	4.42	4.99	6.79	6.16	4.15	4.41	5.54	4.74
Market Cap	4.70B	2.56B	3.31B	2.70B	2.12B	2.31B	3.03B	2.62B	1.66B	1.66B	2.00B	1.63B
Enterprise Value	4.40B	2.30B	2.94B	2.39B	1.90B	2.13B	2.79B	2.35B	1.42B	1.45B	1.78B	1.42B
Calculated Values
Free Cash Flow TTM	165.99M	155.34M	126.63M	98.21M	83.97M	78.45M	63.81M	56.48M	40.13M	26.33M	34.26M	29.08M
Net Debt	-299.52M	-264.79M	-364.23M	-315.57M	-219.50M	-186.12M	-239.09M	-274.08M	-235.92M	-209.19M	-217.33M	-202.46M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
PEG Ratio
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
EV Revenue TTM
EV FCF TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2026-06-18Sale

Owner: Eastham, Karin

Title: -

Shares: 3,729

Price/Share: $53.16

Value: $198,233.64

Shares Owned: 15,097

Relationship: Director

Ownership: Direct

2026-06-04Sale

Owner: Mcguire, Annie

Title: EVP, General Counsel

Shares: 3,176

Price/Share: $49.72

Value: $157,910.72

Shares Owned: 137,240

Relationship: Officer

Ownership: Direct

2026-06-04Sale

Owner: Chambers, Rebecca

Title: Chief Financial Officer

Shares: 3,561

Price/Share: $49.68

Value: $176,910.48

Shares Owned: 173,280

Relationship: Officer

Ownership: Direct

2026-06-04Sale

Owner: Stapley, Marc

Title: Chief Executive Officer

Shares: 138,051

Price/Share: $50.12

Value: $6,919,116.12

Shares Owned: 440,494

Relationship: Director,Officer

Ownership: Direct

2026-06-04Sale

Owner: Leite, John

Title: Global Chief Commercial Off

Shares: 13,975

Price/Share: $50.07

Value: $699,728.25

Shares Owned: 132,305

Relationship: Officer

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2026-06-18	Eastham, Karin	Director	-	Direct	Sale	3,729	53.16	$198,233.64	15,097	4
2026-06-04	Mcguire, Annie	Officer	EVP, General Counsel	Direct	Sale	3,176	49.72	$157,910.72	137,240	4
2026-06-04	Chambers, Rebecca	Officer	Chief Financial Officer	Direct	Sale	3,561	49.68	$176,910.48	173,280	4
2026-06-04	Stapley, Marc	Director,Officer	Chief Executive Officer	Direct	Sale	138,051	50.12	$6,919,116.12	440,494	4
2026-06-04	Leite, John	Officer	Global Chief Commercial Off	Direct	Sale	13,975	50.07	$699,728.25	132,305	4
2026-05-22	Wygant, Jonathan	Officer	VP, Chief Accounting Officer	Direct	Sale	24,000	45.40	$1,089,600.00	45,434	4
2026-05-20	Epstein, Robert S	Director	-	Direct	Sale	10,000	44.01	$440,100.00	52,446	4
2026-05-06	Mcguire, Annie	Officer	SVP, General Counsel	Direct	Sale	10,204	39.02	$398,160.08	143,708	4
2026-03-04	Leite, John	Officer	Chief Commercial Officer-CLIA	Direct	Sale	5,260	35.19	$185,099.40	107,580	4
2026-03-04	Chambers, Rebecca	Officer	Chief Financial Officer	Direct	Sale	18,341	35.94	$659,175.54	131,196	4
2026-03-04	Mcguire, Annie	Officer	SVP, General Counsel	Direct	Sale	6,658	35.82	$238,489.56	94,706	4
2026-03-04	Stapley, Marc	Director,Officer	Chief Executive Officer	Direct	Sale	45,523	35.92	$1,635,186.16	357,554	4
2026-03-02	Febbo, Phillip G.	Officer	Chief Scientific & Med Officer	Direct	Sale	13,425	36.16	$485,448.00	117,346	4
2025-12-16	Mcguire, Annie	Officer	SVP, General Counsel	Direct	Sale	10,739	43.40	$466,072.60	67,760	4
2025-12-05	Eastham, Karin	Director	-	Direct	Sale	20,000	45.65	$913,000.00	13,554	4
2025-12-04	Mcguire, Annie	Officer	SVP, General Counsel	Direct	Sale	1,422	47.30	$67,260.60	78,499	4
2025-12-04	Chambers, Rebecca	Officer	Chief Financial Officer	Direct	Sale	13,278	46.93	$623,136.54	109,496	4
2025-12-04	Stapley, Marc	Director,Officer	Chief Executive Officer	Direct	Sale	7,668	47.12	$361,316.16	318,603	4
2025-12-04	Leite, John	Officer	Chief Commercial Officer-CLIA	Direct	Sale	1,278	47.51	$60,717.78	82,113	4
2025-11-25	Jones, Evan/ Fa	Director	-	Direct	Sale	1,106	50.25	$55,576.50	29,362	4
2025-11-25	Leite, John	Officer	Chief Commercial Officer-CLIA	Direct	Sale	2,808	50.00	$140,400.00	86,291	4
2025-11-20	Holstein, Jens	Director	-	Direct	Sale	10,000	42.21	$422,100.00	27,199	4
2025-11-10	Wygant, Jonathan	Officer	VP, Chief Accounting Officer	Direct	Sale	5,102	42.33	$215,967.66	38,745	4
2025-11-05	Mcguire, Annie	Officer	SVP, General Counsel	Direct	Sale	6,466	40.00	$258,640.00	82,973	4
2025-11-05	Chambers, Rebecca	Officer	Chief Financial Officer	Direct	Sale	7,000	41.00	$287,000.00	126,158	4
2025-11-05	Eastham, Karin	Director	-	Direct	Sale	9,674	40.02	$387,153.48	13,554	4
2025-11-05	Jones, Evan/ Fa	Director	-	Direct	Sale	43,196	44.29	$1,913,150.84	30,468	4
2025-10-06	Febbo, Phillip G.	Officer	Chief Scientific & Med Officer	Direct	Sale	8,349	36.02	$300,730.98	92,441	4
2025-10-01	Mcguire, Annie	Officer	SVP, General Counsel	Direct	Sale	2,160	35.00	$75,600.00	89,439	4
2025-10-01	Epstein, Robert S	Director	-	Direct	Sale	21,473	35.08	$753,272.84	62,446	4
2025-10-01	Leite, John	Officer	Chief Commercial Officer-CLIA	Direct	Sale	2,539	35.00	$88,865.00	89,099	4
2025-09-19	Mcguire, Annie	Officer	SVP, General Counsel	Direct	Sale	2,283	33.69	$76,914.27	91,599	4
2025-09-04	Stapley, Marc	Director,Officer	Chief Executive Officer	Direct	Sale	7,667	30.41	$233,153.47	334,185	4
2025-06-13	Eastham, Karin	Director	-	Direct	Sale	4,590	26.66	$122,369.40	13,907	4
2025-06-13	Bhanji, Muna	Director	-	Direct	Sale	4,589	26.67	$122,388.63	29,989	4
2025-06-04	Leite, John	Officer	Chief Commercial Officer-CLIA	Direct	Sale	2,809	27.20	$76,404.80	94,540	4
2025-03-07	Leite, John	Officer	Chief Commercial Officer-CLIA	Direct	Sale	7,411	31.50	$233,446.50	100,249	4
2025-03-04	Mcguire, Annie	Officer	SVP, General Counsel	Direct	Sale	1,142	33.69	$38,473.98	70,308	4
2025-03-04	Stapley, Marc	Director,Officer	Chief Executive Officer	Direct	Sale	52,697	33.70	$1,775,888.90	268,035	4
2025-03-04	Febbo, Phillip G.	Officer	Chief Scientific & Med Officer	Direct	Sale	8,037	33.40	$268,435.80	82,540	4
2025-02-27	Leite, John	Officer	Chief Commercial Officer-CLIA	Direct	Sale	5,746	33.84	$194,444.64	79,070	4
2025-02-03	Chambers, Rebecca	Officer	Chief Financial Officer	Direct	Sale	527	43.85	$23,108.95	113,510	4
2025-01-02	Eastham, Karin	Director	-	Direct	Sale	10,000	40.31	$403,100.00	18,497	4
2024-12-13	Stapley, Marc	Director,Officer	Chief Executive Officer	Direct	Sale	5,590	43.76	$244,618.40	307,345	4
2024-12-04	Mcguire, Annie	Officer	SVP, General Counsel	Direct	Sale	18,699	44.02	$823,129.98	72,869	4
2024-12-04	Febbo, Phillip G.	Officer	Chief Scientific & Med Officer	Direct	Sale	3,934	44.09	$173,450.06	82,414	4
2024-12-03	Wygant, Jonathan	Officer	VP, Chief Accounting Officer	Direct	Sale	956	43.36	$41,452.16	40,270	4
2024-12-03	Chambers, Rebecca	Officer	Chief Financial Officer	Direct	Sale	7,000	43.23	$302,610.00	114,037	4
2024-12-03	Leite, John	Officer	Chief Commercial Officer-CLIA	Direct	Sale	1,050	43.25	$45,412.50	73,810	4
2024-11-27	Wygant, Jonathan	Officer	VP, Chief Accounting Officer	Direct	Sale	5,032	42.89	$215,822.48	42,313	4
2024-11-19	Eastham, Karin	Director	-	Direct	Sale	14,731	37.77	$556,389.87	18,497	4
2024-11-12	Chambers, Rebecca	Officer	Chief Financial Officer	Direct	Sale	15,275	38.34	$585,643.50	124,501	4
2024-11-12	Epstein, Robert S	Director	-	Direct	Sale	15,000	38.32	$574,800.00	44,598	4
2024-09-19	Jones, Evan/ Fa	Director	-	Indirect	Sale	5,173	35.23	$182,244.79	0	4
2024-09-04	Leite, John	Officer	Chief Commercial Officer-CLIA	Direct	Sale	5,479	29.78	$163,164.62	76,174	4
2024-08-13	Jones, Evan/ Fa	Director	-	Direct	Sale	20,457	32.11	$656,874.27	34,343	4
2024-08-09	Jones, Evan/ Fa	Director	-	Direct	Sale	1,032	30.03	$30,990.96	46,413	4
2024-08-07	Holstein, Jens	Director	-	Direct	Sale	5,000	29.00	$145,000.00	27,878	4
2024-08-07	Jones, Evan/ Fa	Director	-	Direct	Sale	3,143	30.32	$95,295.76	47,145	4/A
2024-07-16	Holstein, Jens	Director	-	Direct	Sale	5,000	24.50	$122,500.00	32,878	4
2024-07-16	Leite, John	Officer	Chief Commercial Officer-CLIA	Direct	Sale	1,277	25.00	$31,925.00	82,968	4
2024-07-16	Eastham, Karin	Director	-	Direct	Sale	7,500	25.00	$187,500.00	33,228	4
2024-06-11	Eastham, Karin	Director	-	Direct	Sale	3,870	20.59	$79,683.30	29,255	4
2024-06-10	Bhanji, Muna	Director	-	Direct	Sale	3,870	20.32	$78,638.40	23,105	4
2024-06-07	Eastham, Karin	Director	-	Direct	Sale	2,500	20.97	$52,425.00	33,125	4
2024-05-28	Bhanji, Muna	Director	-	Direct	Sale	1,539	21.00	$32,319.00	26,975	4
2024-04-01	Eastham, Karin	Director	-	Direct	Sale	10,000	21.65	$216,500.00	33,125	4
2024-03-01	Jones, Evan/ Fa	Director	-	Direct	Sale	10,000	24.36	$243,600.00	37,601	4
2023-07-19	Jones, Evan/ Fa	Director	-	Direct	Sale	838	30.14	$25,257.32	37,601	4
2023-07-18	Bishop, John L	Director	-	Direct	Sale	10,000	30.50	$305,000.00	33,125	4
2023-07-18	Jones, Evan/ Fa	Director	-	Direct	Sale	2,324	30.16	$70,091.84	38,439	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

107.21%

Inst. Shares: 85,270,513

Shares Outstanding: 79,536,601

2025-12-31

108.01%

Inst. Shares: 84,879,163

Shares Outstanding: 78,584,291

2025-09-30

111.59%

Inst. Shares: 87,846,478

Shares Outstanding: 78,725,139

2025-06-30

104.21%

Inst. Shares: 81,693,157

Shares Outstanding: 78,391,502

2025-03-31

103.12%

Inst. Shares: 80,463,843

Shares Outstanding: 78,028,254

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	85,270,513	79,536,601	107.21%
2025-12-31	84,879,163	78,584,291	108.01%
2025-09-30	87,846,478	78,725,139	111.59%
2025-06-30	81,693,157	78,391,502	104.21%
2025-03-31	80,463,843	78,028,254	103.12%
2024-12-31	77,365,373	76,484,759	101.15%
2024-09-30	76,593,964	77,013,831	99.45%
2024-06-30	77,406,912	76,538,325	101.13%
2024-03-31	77,374,842	74,759,789	103.50%
2023-12-31	73,532,492	72,644,487	101.22%
2023-09-30	72,955,709	72,804,770	100.21%
2023-06-30	71,374,773	72,478,662	98.48%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

VERACYTE, INC. (VCYT) — SEC Financial Statements & Analysis

VERACYTE, INC. (VCYT) is a services-medical laboratories company, incorporated in DE. VERACYTE, INC. trades on Nasdaq as: VCYT. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), VERACYTE, INC. reported a 17.28% year-over-year revenue growth, a Gross Profit Margin of 71.71% (TTM), a Debt-to-Equity ratio of 0.07x, a Price-to-Sales (P/S) ratio of 8.36x (TTM), a Price-to-Book (P/B) ratio of 3.38x (TTM), at a market cap of $4.70B. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y: 17.28%
Gross Profit Margin TTM: 71.71%
Debt To Equity: 0.07x
P/S TTM: 8.36x
P/B TTM: 3.38x
Market Cap: $4.70B

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is VERACYTE, INC. in?

VERACYTE, INC. (VCYT) operates in the Services-Medical Laboratories industry.

What is VCYT's market cap?

VERACYTE, INC. (VCYT) has a market capitalization of $4.70B as of 2026-06-30.

What is VCYT's P/E ratio?

VERACYTE, INC. (VCYT)'s trailing twelve month P/E ratio is 41.03x as of 2026-06-30.

What exchange does VCYT trade on?

VERACYTE, INC. (VCYT) trades on the Nasdaq.

Where is VERACYTE, INC. incorporated?

VERACYTE, INC. is incorporated in DE.

VERACYTE, INC.

Financial Statements

Custom Table

Interactive Financial Visualizations

Earnings Market Reaction

Performance and Valuation Metrics

Insider Transactions

Institutional Ownership

VERACYTE, INC. (VCYT) — SEC Financial Statements & Analysis

Frequently Asked Questions

Companies in Services-Medical Laboratories

Wall Street's data.
Main Street's price.

VERACYTE, INC. (VCYT) — SEC Financial Statements & Analysis

Frequently Asked Questions

Companies in Services-Medical Laboratories

Wall Street's data.Main Street's price.

Wall Street's data.
Main Street's price.